Ep. 4: Navigating the Biotech Landscape | Biotech Bulls & Breakthroughs Podcast

What It Covers

Veteran biotech trader Chef Station and BioPharm Catalyst's John Galliano review August 2025 market conditions, dissect Viking Therapeutics' oral obesity drug failure, and walk through 15+ specific small-to-mid-cap catalyst plays across August and September 2025, covering PDUFA dates, IND acceptances, NDA submissions, and phase trial data readouts.

Key Questions Answered

• •Viking Therapeutics failure signals GLP-1 risk: Viking's oral obesity drug posted a 28% patient dropout rate over just 13 weeks, compared to Eli Lilly's similar dropout rate over 72 weeks — a dramatically inferior profile. Traders should reassess small-cap companies banking on GLP-1 acquisition premiums, as this data casts doubt on the near-term oral obesity pipeline and reinforces Lilly and Novo Nordisk's dominant positioning.
• •Biotech earnings screening framework: During earnings season, ignore revenue for pre-commercial biotech. Instead screen for three signals: cash runway relative to upcoming catalysts, absence of long-term debt, and new institutional investors such as RA Capital or Orbimed taking positions. A company with $150–200M cash, zero debt, and a major fund entering at 10% signals acquisition readiness and de-risked catalyst trading.
• •OSTX August 27 end-of-phase-two meeting: OS Therapeutics holds an FDA end-of-phase-two meeting on August 27 targeting a rolling BLA with potential December approval. A successful outcome triggers a priority review voucher worth $150–200M — exceeding the company's current sub-$100M market cap. The drug treats osteosarcoma in both dogs and humans, addressing the leading non-accident cause of canine death.
• •PMVP September 10 interim analysis: PMV Pharmaceuticals carries $165M cash with runway into 2026 and releases interim phase two PINNACLE trial data on September 10 — 50 patients with 18-week follow-up targeting TP53 tumor mutations across multiple cancer types. The open-label single-study design reduces placebo noise. Johnson & Johnson-style institutional backing and a defined catalyst date create a tradeable pre-data run setup.
• •Low float structure amplifies catalyst moves: Several September plays — REVB with 1.6M shares in float, RLYB under 30M shares, ARTL at 1.2M float — demonstrate how sub-2M share structures magnify price movement on catalyst news. When volume spikes on a 1–2M float stock, even modest buying pressure produces outsized percentage gains. Prioritize float size alongside catalyst date when sizing positions in small-cap biotech.
• •Key Q4 conferences drive September positioning: The American Society of Hematology and San Antonio Breast Cancer Conference, both in early December, trigger abstract and oral presentation announcements in mid-to-late September. Traders should build watchlists now around companies likely to receive presentation slots — particularly smaller-cap oncology names like Merus — as September announcement dates function as standalone catalysts before the actual conference data drops.